Literature DB >> 28844817

Labetuzumab govitecan in metastatic colorectal cancer.

Manjulika Das.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28844817     DOI: 10.1016/S1470-2045(17)30664-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

1.  Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.

Authors:  Carl M Gay; C Allison Stewart; Elizabeth M Park; Lixia Diao; Sarah M Groves; Simon Heeke; Barzin Y Nabet; Junya Fujimoto; Luisa M Solis; Wei Lu; Yuanxin Xi; Robert J Cardnell; Qi Wang; Giulia Fabbri; Kasey R Cargill; Natalie I Vokes; Kavya Ramkumar; Bingnan Zhang; Carminia M Della Corte; Paul Robson; Stephen G Swisher; Jack A Roth; Bonnie S Glisson; David S Shames; Ignacio I Wistuba; Jing Wang; Vito Quaranta; John Minna; John V Heymach; Lauren Averett Byers
Journal:  Cancer Cell       Date:  2021-01-21       Impact factor: 31.743

Review 2.  The Potential of Topoisomerase Inhibitor-Based Antibody-Drug Conjugates.

Authors:  Seungmin Han; Kwang Suk Lim; Brody J Blackburn; Jina Yun; Charles W Putnam; David A Bull; Young-Wook Won
Journal:  Pharmaceutics       Date:  2022-08-16       Impact factor: 6.525

Review 3.  Antibody-drug conjugates: beyond current approvals and potential future strategies.

Authors:  Siddharth Menon; Sagun Parakh; Andrew M Scott; Hui K Gan
Journal:  Explor Target Antitumor Ther       Date:  2022-04-28

4.  SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures.

Authors:  Camille Tlemsani; Lorinc Pongor; Fathi Elloumi; Luc Girard; Kenneth E Huffman; Nitin Roper; Sudhir Varma; Augustin Luna; Vinodh N Rajapakse; Robin Sebastian; Kurt W Kohn; Julia Krushkal; Mirit I Aladjem; Beverly A Teicher; Paul S Meltzer; William C Reinhold; John D Minna; Anish Thomas; Yves Pommier
Journal:  Cell Rep       Date:  2020-10-20       Impact factor: 9.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.